Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of ANAVEX2-73 in Parkinson's disease dementia
2019-002678-29Phase 2Active
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blarcamesine in Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), sponsored by Anavex Life Sciences Corp. Primary endpoint: Safety Evaluation. Started Oct 2019; status: active.
02
Drugs
blarcamesine
03
Conditions
Parkinson's disease dementia (PDD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on 2019-002678-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002678-29.